Zamron Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-12-2024
- Paid Up Capital ₹ 0.10 M
as on 22-12-2024
- Company Age 8 Year, 4 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 88.52%
(FY 2022)
- Ebitda 88.52%
(FY 2022)
- Net Worth -1.12%
(FY 2022)
- Total Assets -6.88%
(FY 2022)
About Zamron Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Tarun Garg and Nidhi Garg serve as directors at the Company.
- CIN/LLPIN
U74999HR2016PTC066899
- Company No.
066899
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Karnal, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Zamron Lifescience Private Limited offer?
Zamron Lifescience Private Limited offers a wide range of products and services, including Antiemetic Drugs, Domperidone Tablet, Antacid Drugs, Rabeprazole Tablets, Multivitamin Tablets & Capsules, Iron Folic Acid Tablet, Pharmaceutical Medicine, Lycopene Syrup, Multivitamin Syrup & Drops, Vitamin B Complex Syrup.
Who are the key members and board of directors at Zamron Lifescience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tarun Garg  | Director | 30-Dec-2016 | Current |
| Nidhi Garg | Director | 30-Dec-2016 | Current |
Financial Performance of Zamron Lifescience.
Zamron Lifescience Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 88.52% increase in profit. The company's net worth dipped by a decrease of 1.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zamron Lifescience?
In 2022, Zamron Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zamron Lifescience?
Unlock and access historical data on people associated with Zamron Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zamron Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zamron Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
